Abstract 147P
Background
In resectable esophageal squamous cell carcinoma (ESCC), there is limited evidence of the efficacy of serplulimab in combination with chemotherapy followed by minimally invasive esophagectomy. Therefore, we aimed to observe and evaluate its efficacy and safety in locally advanced ESCC.
Methods
Patients aged 18-75 years and classified as stage II-IVA according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual, who were histologically or cytologically diagnosed with ESCC, were deemed eligible to participate in this trial. Patients received 3 cycles of neoadjuvant therapy with serplulimab (4.5mg/kg intravenously on day 1), carboplatin (AUC=5 intravenously on day 1), albumin paclitaxel (260 mg/m2 intravenously on day 1); each cycle was repeated every 21 days. Surgery occurred 4-6 weeks after the last neoadjuvant treatment cycle. The primary outcome was the pathological complete response (PCR) rate of the tumour and lymph nodes. This prospective, single-arm, phase 2 trial was conducted at the Second Affiliated Hospital of Zhejiang University in China.
Results
A total of 48 patients were enrolled in this study, with no observed disease progression during the neoadjuvant treatment phase. The disease control rate and objective response rate were 100.0% and 68.8%, respectively. Most of the adverse events were grade 1-2, 2 (4.2%) patients experienced grade 3 adverse events. Three patients refused to receive surgical treatment and declined to participate in the study. Consequently, 45 patients received minimally invasive esophagectomy. All 45 patients achieved R0 resection, with 14 patients (31.1%) attaining a PCR for both the tumour and lymph nodes.
Conclusions
The administration of serplulimab in conjunction with chemotherapy in the neoadjuvant setting for locally advanced ESCC has demonstrated promising antitumor activity and an acceptable safety profile in this single-arm study. Extended follow-up to assess survival outcomes and a phase 3 randomized trial are necessary to further evaluate the efficacy and safety of the proposed treatment regimen.
Clinical trial identification
NCT05659251.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract